OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 22:13 UTC. Every row links to its source record.

H3-3A H3.3 histone A

ENSG00000163041 · protein coding · Open Targets profile

Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. {ECO:0000269|PubMed:14718166, ECO:0000269|PubMed:15776021, ECO:0000269|PubMed:16258499}.

In 13 of 15 cancers, the evidence for H3-3A comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751gliomagliomaglioma: somatic 0.61glioma: germline 0.87malignant gliomamalignant gliomamalignant glioma: somatic 0.76breast carcinomabreast carcinomabreast carcinoma: somatic 0.46pilocytic astrocytomapilocytic astrocytomapilocytic astrocytoma: somatic 0.54bone giant cell tumorbone giant cell tumorbone giant cell tumor: somatic 0.61astrocytoma (excluding glioblastoma)astrocytoma (excluding glioblastoma)astrocytoma (excluding glioblastoma): somatic 0.61spinal cord astrocytomaspinal cord astrocytomaspinal cord astrocytoma: somatic 0.61anaplastic astrocytomaanaplastic astrocytomaanaplastic astrocytoma: somatic 0.61brain astrocytomabrain astrocytomabrain astrocytoma: somatic 0.61melanomamelanomaTransitional MeningiomaTransitional MeningiomaTransitional Meningioma: somatic 0.61brain glioblastomabrain glioblastomabrain glioblastoma: somatic 0.61gangliogliomagangliogliomaganglioglioma: somatic 0.61anaplastic oligoastrocytomaanaplastic oligoastrocytomaanaplastic oligoastrocytoma: somatic 0.61brain gliomabrain gliomabrain glioma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e – (upper bound –). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of H3-3A's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of H3-3A's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.